-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
During a migraine attack, the initial mild pain usually escalates to moderate or severe pain
Recently, a research article was published in Neurology, an authoritative journal in the field of neurology.
In this phase 3, open-label, dose-blind, 52-week trial, adults with migraine were randomized 1:1 (usually, ubbrosu-50 mg, or ublosu-100 mg)
The study included data on 19,291 migraine attacks from 808 participants
CONCLUSIONS: Compared with moderate or severe pain episodes, patients with mild pain had significantly higher rates of pain relief, associated symptoms, and return to normal function within 2 hours of treatment with Ubroxide
Original source:
Richard B.